PO-05-111 IMPLANTING A NOVEL ACTIVE-FIXATION LEADLESS PACEMAKER: A SINGLE CENTER EXPERIENCE WITH THE AVEIR VR

The new Aveir VR (Abbott Medical, CA) active-fixation leadless pacemaker (LP) offers several novel innovations. It uses a unique mapping capability to help reduce repositioning attempts prior fixation and utilizes helical mechanism for implantation chronic retrieval. We describe the current largest real world descriptive single center experience with LP. This retrospective study describes characteristics outcomes of patients who underwent chamber LP between May 2022 December 2022. Data was collected from patients’ electronic medical records, dictation forms procedural logs. Variables included demographics (eg age, sex, race), procedure length, fluoroscopic duration), hospital length stay time discharge, pacing parameters complications. A total 48 most common indications were symptomatic bradycardia due sinus node dysfunction (55%) atrial fibrillation (29%). average age 72.5 years, 51% male, 53% African Americans. duration 34.3 minutes (range 15–106) fluoroscopy 13.4 1.4–41.6). Procedure improved median 36.0 in first 10 cases 26.0 last done by same operator. number locations 1.6 fixation, implant location low septal 84% patients, 8.3% required repositioning. R wave amplitude at 8.3 mV 3.0–18), impedance 789 Ω 380–1800), threshold 0.87V 0.25–2.5) 0.4ms. There no periprocedural complications any implantations. 13 days 0.5–63), however discharge presenting electively 15 hours. Our demonstrates that has been safe effective is comparable trial data.